A federal jury in Boston awarded Teva Pharmaceuticals International GmbH $176.5 million in damages in a patient infringement suit against Eli Lilly and Co. for its migraine medication, Emgality.
Following a trial in the U.S. District Court for the District of Massachusetts, a jury concluded Wednesday that Lilly’s rival medication infringed on three of Teva’s patents covering its migraine medication, Ajovy. Both Emgality and Ajovy work by releasing antibodies capable of treating headache disorders associated with calcitonin gene-related peptide (CGRP).
